AVEO Oncology: A High Risk, High Reward Play [Seeking Alpha]
Bristol-Myers Squibb Company (BMY)
Last bristol-myers squibb company earnings: 2/6 07:05 am
Check Earnings Report
US:NYSE Investor Relations:
bms.com/investors.html
Company Research
Source: Seeking Alpha
Summary Introduction AVEO Oncology ( AVEO ) is a small cap biotechnology company focused in developing its lead product tivozanib (Fotivda ® ), an oral inhibitor of VEGF receptor 1, 2, and 3 tyrosine kinases for the treatment of metastatic renal cell carcinoma (mRCC). Tivozanib is approved for first-line RCC in the EU since August of 2017. This product is sub-licensed out to EUSA Pharma. Despite being approved in the EU, the FDA denied AVEO’s application for approval in the United States. Now, in attempt to prove the efficacy, AVEO is studying tivozanib in the third-line setting. Additionally, AVEO is studying tivozanib in combination with Bristol-Myers Squibb’s ( BMY ) workhorse nivolumab (Opdivo ® ). With readouts from both trials scheduled in the coming weeks, here I will outline each trial and the fundamentals of AVEO, underscoring why these results could be a make or break situation for the company and investors. Tivozanib plus Nivolumab – Background This trial
Show less
Read more
Impact Snapshot
Event Time:
BMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMY alerts
High impacting Bristol-Myers Squibb Company news events
Weekly update
A roundup of the hottest topics
BMY
News
- Could Investing $100,000 in Bristol Myers Squibb Stock Make You a Millionaire? [Yahoo! Finance]Yahoo! Finance
- Lykos Therapeutics Strengthens Commercial Organization with Key Hires as it Prepares for Potential Commercial Launch [Yahoo! Finance]Yahoo! Finance
- Bristol-Myers Squibb: A Lost Decade? [Seeking Alpha]Seeking Alpha
- FTC plans to recommend a possible criminal case against ex-Pioneer CEO [Yahoo! Finance]Yahoo! Finance
- Schrödinger Reports First Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
BMY
Earnings
- 4/25/24 - Miss
BMY
Sec Filings
- 5/3/24 - Form 4
- 4/25/24 - Form 10-Q
- 4/25/24 - Form 8-K
- BMY's page on the SEC website